Track market-moving stories before they get noisy

Posted by Defense World Staff on Apr 20th, 2026

Davidson Investment Advisors cut its position in shares of Camden Property Trust (NYSE:CPT – Free Report) by 4.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,964 shares of the real estate investment trust’s stock after selling 6,954 shares during the period. Davidson Investment Advisors owned approximately 0.15% of Camden Property Trust worth $17,279,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of CPT. Abich Financial Wealth Management LLC purchased a new position in Camden Property Trust during the third quarter worth about $25,000. Quent Capital LLC purchased a new position in Camden Property Trust during the third quarter worth about $29,000. Hantz Financial Services Inc. raised its stake in Camden Property Trust by 524.4% during the third quarter. Hantz Financial Services Inc. now owns 281 shares of the real estate investment trust’s stock worth $30,000 after purchasing an additional 236 shares during the period. CYBER HORNET ETFs LLC purchased a new position in Camden Property Trust during the second quarter worth about $32,000. Finally, Fulcrum Asset Management LLP purchased a new position in Camden Property Trust during the third quarter worth about $32,000. 97.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity In other news, COO Laurie Baker sold 2,168 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $108.40, for a total value of $235,011.20. Following the sale, the chief operating officer directly owned 94,468 shares of the company’s stock, valued at approximately $10,240,331.20. The trade was a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.90% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have commented on CPT shares. Scotiabank reduced their target price on shares of Camden Property Trust from $115.00 to $113.00 and set a “sector perform” rating on the stock in a research note on Wednesday, March 4th. Cantor Fitzgerald lifted their target price on shares of Camden Property Trust from $105.00 to $108.00 and gave the stock a “neutral” rating in a research note on Monday, February 9th. Wall Street Zen raised shares of Camden Property Trust from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Camden Property Trust in a research note on Wednesday, January 21st. Finally, Mizuho lifted their target price on shares of Camden Property Trust from $114.00 to $120.00 and gave the stock an “outperform” rating in a research note on Monday, January 12th. Five analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $115.16.

View Our Latest Report on CPT

Camden Property Trust Price Performance Camden Property Trust stock opened at $103.52 on Monday. The company’s 50 day simple moving average is $103.64 and its 200-day simple moving average is $104.75. The company has a market capitalization of $10.84 billion, a price-to-earnings ratio of 29.24, a price-to-earnings-growth ratio of 7.04 and a beta of 0.83. Camden Property Trust has a 1 year low of $96.53 and a 1 year high of $121.33. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.14 and a current ratio of 0.14.

Camden Property Trust (NYSE:CPT – Get Free Report) last released its quarterly earnings results on Thursday, February 5th. The real estate investment trust reported $1.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.73 by ($0.29). The company had revenue of $396.08 million during the quarter, compared to analysts’ expectations of $393.05 million. Camden Property Trust had a net margin of 24.43% and a return on equity of 8.36%. Camden Property Trust’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $1.73 earnings per share. Camden Property Trust has set its Q1 2026 guidance at 1.640-1.680 EPS and its FY 2026 guidance at 6.600-6.900 EPS. As a group, equities research analysts expect that Camden Property Trust will post 6.76 earnings per share for the current year.

Camden Property Trust announced that its Board of Directors has authorized a stock repurchase program on Thursday, February 5th that allows the company to buyback $600.00 million in outstanding shares. This buyback authorization allows the real estate investment trust to purchase up to 5.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s leadership believes its shares are undervalued.

Camden Property Trust Increases Dividend The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Stockholders of record on Tuesday, March 31st were paid a $1.06 dividend. This is a positive change from Camden Property Trust’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend was Tuesday, March 31st. This represents a $4.24 dividend on an annualized basis and a dividend yield of 4.1%. Camden Property Trust’s payout ratio is presently 119.77%.

Camden Property Trust Profile (Free Report)

Camden Property Trust is a publicly traded real estate investment trust (REIT) specializing in the ownership, development and management of multifamily residential communities across the United States. The company’s core business activities include acquiring land for new construction, overseeing the design and development of garden-style and mid-rise apartment communities, and providing ongoing property management services. Camden’s asset management team focuses on maintaining high occupancy levels, resident satisfaction and operational efficiency through consistent leasing, maintenance and community engagement programs.

Camden’s portfolio encompasses a geographically diversified mix of properties located primarily in high-growth Sun Belt and major metropolitan markets.

Featured Articles Five stocks we like better than Camden Property Trust

Receive News & Ratings for Camden Property Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Camden Property Trust and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDavidson Investment Advisors Purchases 16,838 Shares of VanEck Intermediate Muni ETF $ITM

NEXT HEADLINE »Davidson Investment Advisors Has $18.72 Million Stake in Philip Morris International Inc. $PM

HOUSTON--(BUSINESS WIRE)--Camden Property Trust (NYSE:CPT) (the "Company") announced today operating results for the three months ended March 31, 2026. Net Income Attributable to Common Shareholders (“EPS”), Funds from Operations (“FFO”), Core Funds from Operations ("Core FFO"), and Core Adjusted Funds from Operations (“Core AFFO”) for the three months ended March 31, 2026 are detailed below. A reconciliation of EPS to FFO, Core FFO, and Core AFFO is included in the financial tables accompanyin.

Camden (CPT - Free Report) came out with quarterly funds from operations (FFO) of $1.7 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to FFO of $1.72 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an FFO surprise of +2.10%. A quarter ago, it was expected that this real estate investment trust would post FFO of $1.73 per share when it actually produced FFO of $1.76, delivering a surprise of +1.73%.

Over the last four quarters, the company has surpassed consensus FFO estimates four times.

Camden, which belongs to the Zacks REIT and Equity Trust - Residential industry, posted revenues of $388.77 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 0.48%. This compares to year-ago revenues of $390.57 million. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.

Camden shares have lost about 4.3% since the beginning of the year versus the S&P 500's gain of 4.2%.

What's Next for Camden?While Camden has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Camden was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $1.66 on $394.76 million in revenues for the coming quarter and $6.74 on $1.58 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Residential is currently in the bottom 30% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

American Homes 4 Rent (AMH - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 6.

This real estate company is expected to post quarterly earnings of $0.48 per share in its upcoming report, which represents a year-over-year change of +4.4%. The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level.

American Homes 4 Rent's revenues are expected to be $467.48 million, up 1.8% from the year-ago quarter.

Key Takeaways CPT's Q1 core FFO was $1.70 per share, beating consensus even as property revenues fell.Camden's same-property NOI slipped 0.7% as expenses rose 1.9%, and blended lease rates hit -1.4%.CPT sold a Texas community, marketed 11 in California, bought 2 after quarter-end. Camden Property Trust (CPT - Free Report) reported first-quarter 2026 core funds from operations (FFO) per share of $1.70, beating the Zacks Consensus Estimate of $1.67 by 1.8%. Core FFO dipped 1.2% year over year from $1.72.

Property revenues were $388.8 million, down 0.5% year over year and modestly below the consensus estimate of $390.7 million (a -0.5% surprise). Same-property occupancy averaged 95.1% for the quarter.

Camden's Same-Property Fundamentals Stay PressuredOperating trends continued to show modest top-line traction and cost pressure. Same-property revenues rose 0.2% year over year, while same-property expenses increased 1.9%, resulting in a 0.7% decline in same-property net operating income (NOI).

Leasing spreads remained soft on new move-ins, while renewals provided partial support. Effective new lease rates were down 5.2% versus expiring leases, and effective renewal rates increased 2.9%, leading to effective blended lease rates of negative 1.4% for the quarter.

CPT's Development and Transaction Activity Remain ActiveLeasing continued at Camden Village District in Raleigh, NC, where construction is complete, and the community was 72% leased as of April 29, 2026. Beyond that, the company had three communities under construction totaling 1,162 apartment homes at an estimated total cost of $492.0 million.

Transaction activity extended beyond development. During the quarter, Camden began marketing 11 operating communities in California for sale and disposed of Camden Valley Park, a 516-home community in Irving, TX, for about $77.0 million. Subsequent to quarter-end, the company acquired Camden Alpharetta (269 homes) and Camden at Lake Nona (288 homes) for a combined $171.3 million.

Camden Details Funding Position, Highlights BuybacksCPT ended the quarter with approximately $881.9 million of liquidity, comprising $40.7 million of cash and cash equivalents and $841.2 million of availability under its unsecured credit facility and commercial paper program. It also had about $176.6 million left to fund within its wholly owned development pipeline.

Leverage increased, with net debt to annualized adjusted EBITDAre at 4.7X compared with 4.1X a year earlier. Interest expense climbed to $37.4 million from $33.8 million in the prior-year quarter. CPT also issued $600 million of senior unsecured notes due 2036 during the quarter and extended the maturity of its $1.2 billion revolving credit facility to March 2030.

Camden continued to lean on share repurchases. During the quarter, it repurchased 2.63 million shares at an average price of $105.88 per share for a total of $278.8 million. Repurchases remained active after quarter-end, with 1.43 million shares bought back at an average price of $100.78 for $144.1 million. So far in the year, the company has repurchased 4.06 million shares for $422.9 million and has $297.8 million remaining under its stock repurchase program.

CPT Updates Guidance, Maintains Same-Property AssumptionsFor second-quarter 2026, Camden guided core FFO per share in the band of $1.65-$1.69. The Zacks Consensus Estimate presently stands at $1.66.

For full-year 2026, core FFO per share guidance remained in the $6.60-$6.90 range. The Zacks Consensus Estimate of $6.74 lies within the guided range.

CPT maintained its same-property growth assumptions. Full-year same-property revenue growth is expected to range from a decline of 0.25% to an increase of 1.75%, while expenses are projected to rise 2.25% to 3.75%. Same-property NOI is forecast between a 2.50% decline and a 1.50% increase.

Camden recorded a $53.0 million litigation settlement-related charge in the quarter after signing a post-quarter term sheet, but said that the settlement payments will not affect its 2026 core FFO or core AFFO. As such, the company noted that its 2026 core FFO guidance excludes roughly 65 cents per share of non-core charges for legal costs and settlements and expensed transaction pursuit costs.

CPT's Zacks RankCamden currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Other Residential REITsAvalonBay Communities, Inc. (AVB - Free Report) reported first-quarter 2026 core FFO per share of $2.83, beating the Zacks Consensus Estimate of $2.80 by 1.1%. Total revenues came in at $770.3 million, up 3.3% year over year and essentially in line with the consensus mark of $770.6 million.

AvalonBay’s same-store economic occupancy held at 96.1%, underscoring steady demand heading into the peak leasing season. The quarter benefited from incremental development NOI and commercial NOI. However, higher interest expenses undermined the performance of AvalonBay to an extent.

Equity Residential (EQR - Free Report) reported first-quarter 2026 normalized FFO of 99 cents per share, up 4.2% year over year and ahead of the Zacks Consensus Estimate of 95 cents by 4.2%. Rental income grew 2.5% year over year to $779.8 million but came in 0.3% below the consensus mark of $782.6 million.

Equity Residential’s operating fundamentals were supported by steady occupancy and improving coastal-market momentum. Same-store performance remained strong, with revenue growth outpacing prior-quarter momentum and occupancy staying firm. Equity Residential’s management emphasized strength in San Francisco and New York, citing solid demand from higher-earning renters and moderating new supply across its markets.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.

Camden Property Trust (CPT) Q1 2026 Earnings Call Highlights: Strong Revenue and Strategic Financial Moves Amid Market Challenges Camden Property Trust (CPT) surpasses earnings expectations with strategic financial maneuvers and robust market demand, despite facing non-core charges and supply pressures. Summary

Core FFO: $1.70 per share, exceeding guidance midpoint by $0.04.First Quarter Revenue: Higher revenues from operating properties due to lower-than-anticipated bad debt and higher collections on delinquent rent.Property Expense Savings: Contributed $0.02 to outperformance, largely timing related.Non-Core FFO Charges: $58.2 million, primarily from a $53 million class action lawsuit settlement.Same-Store Revenue Guidance: Midpoint reaffirmed at 0.75% for full year 2026.Same-Store Expense Guidance: Midpoint reaffirmed at 3% for full year 2026.Same-Store NOI Guidance: Midpoint remains unchanged at negative 0.5% for full year 2026.Full Year Core FFO Guidance: Midpoint of $6.75 per share.Second Quarter Core FFO Guidance: Expected range of $1.65 to $1.69 per share.Share Repurchases: $423 million at an average price of $104.08 per share during and subsequent to the quarter.Unsecured Bonds Issuance: $600 million of 10-year bonds at an effective rate of 5%.Unsecured Revolving Line of Credit: $1.2 billion recast, extending maturity and lowering pricing by 15 basis points.

Release Date: May 01, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points Camden Property Trust CPT recorded its lowest bad debt level since the onset of COVID-19, attributed to enhanced resident credit screening and increased tax refunds.The company is experiencing strong demand in its markets, particularly in Dallas-Fort Worth, which remains a top destination for headquarter relocations.Camden Property Trust (CPT) has been recognized as a great workplace, ranking 13th on the Fortune Best Place to Work list in America for the 19th consecutive year.The company successfully disposed of a high CapEx community in Dallas, generating a 12% unlevered IRR over a nearly 30-year hold period.Camden Property Trust (CPT) has a strong liquidity position, having recast its $1.2 billion unsecured revolving line of credit and issued $600 million of 10-year unsecured bonds at a 5% rate. Negative Points The company's first quarter outperformance was mainly driven by timing-related items, which may not be sustainable throughout the year.Camden Property Trust (CPT) is facing challenges with new supply pressure, which is expected to moderate as the year progresses.The company recorded $58.2 million of non-core FFO charges, primarily due to a $53 million class action lawsuit settlement.Houston's market performance has been impacted by negative consumer sentiment, despite strong job creation and population growth.Camden Property Trust (CPT) anticipates a sequential decline in core FFO per share for the second quarter, driven by seasonal expenses and timing of merit increases. Q & A Highlights Q: Could you talk about the expected ramp in lease spreads for the rest of the year and any early signs of improvement?
A: Ric Campo, Executive Chairman, explained that April occupancy was around 95.4%, up from 95.1% in the first quarter. Blended rates in April improved by about 100 basis points compared to the first quarter. The company anticipates a strong third quarter as new supply is absorbed, leading to a better-than-usual fourth quarter. Markets like Atlanta, Dallas, Orlando, Nashville, Raleigh, and Southeast Florida are showing positive signs.

Q: Can you discuss the trend in concessions and expectations for the rest of the year?
A: Alex Jessett, CEO, stated that Camden does not offer concessions, but they have observed a significant reduction in concessions across most markets due to decreased new supply. The company is seeing fewer developers offering concessions as they no longer need to rapidly fill new properties.

Q: What are your expectations for renewal lease rates, and how do they compare to previous quarters?
A: Laurie Baker, COO, noted that renewal offers for May, June, and July are in the mid-3% range. The company is seeing less price sensitivity and expects to achieve slightly higher increases as they enter peak leasing season. Resident retention remains high, which supports their pricing strategy.

Q: How does Camden view the potential benefits of scale and data in the context of industry consolidation?
A: Alex Jessett, CEO, emphasized that bigger is not necessarily better. Camden believes it has sufficient data to make informed decisions and does not see significant benefits from being larger. The company focuses on using its existing data effectively to drive performance.

Q: Can you provide insights into the acquisition environment and cap rates in Sunbelt markets?
A: An unidentified company representative mentioned that transaction volumes are below pre-COVID levels but are similar to 2025. Cap rates for newer, well-located properties in the Sunbelt are stable, ranging from 4.5% to 5%. The company is actively evaluating opportunities to redeploy proceeds from its California sale.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

HOUSTON--(BUSINESS WIRE)--Camden Property Trust (NYSE:CPT) (the “Company”) announced today it will participate in the Nareit REITweek 2026 Investor Conference on Tuesday, June 2 and Wednesday, June 3, 2026. The Company also provided an update on second quarter 2026 operating trends, indicating that performance to date is in line with guidance and expectations provided in conjunction with its first quarter 2026 earnings release. A copy of Camden's most recent Investor Presentation can be found i.

Key Takeaways Camden cited one of its strongest first-quarter apartment absorption periods since 2016.CPT expects falling new supply across most markets and 2026 same-property expense growth of 2.25-3.75%.Camden plans $1.0-$1.2B of acquisitions and $1.6-$2.0B of dispositions in 2026. Shares of Camden Property Trust (CPT - Free Report) have risen 9.1% over the past six months against the industry’s 0.2% decline.

Camden benefits from durable renter demand in large Sunbelt markets where migration and steep homeownership costs support apartment needs. Operations remain steady, helped by a diversified urban/suburban mix and continued investment in technology and process efficiency. Capital recycling is advancing, with proceeds expected to be redeployed via exchanges and share repurchases.

Analysts seem bullish about this Zacks Rank #3 (Hold) company. The Zacks Consensus Estimate for CPT’s 2026 funds from operations (FFO) per share has moved 2 cents northward over the past month to $6.76.

Image Source: Zacks Investment Research

Factors Behind CPT’s Stock Price RiseCamden targets metros with in-migration and jobs in higher-wage sectors, which supports steady leasing even when consumer sentiment is mixed. Management noted first-quarter apartment absorption was among the best since 2016 and expects new supply to keep falling across most of its markets.

Camden maintains a broad footprint across 15 major markets and a mix of 41% urban and 59% suburban communities. This blend helps balance exposure to downtown demand shifts and suburban affordability needs. It also allows Camden to optimize pricing by submarket and limit volatility when certain metros face heavier deliveries or slower job growth.

Camden is investing in technology and AI to streamline leasing, reduce repetitive tasks and improve service response times. Management expects expense growth of 2.25% to 3.75% in 2026 on a same-property basis, suggesting these efforts can help offset inflation.

Camden continues to rotate capital by selling older, higher-capex assets and redeploying into core markets. In the first quarter of 2026, it sold a community in Irving, TX, for $77 million and recognized a gain of $67.9 million. Management continues to assume sale proceeds will be reinvested into high-demand Sunbelt markets and share repurchases. For 2026, Camden expects acquisitions of $1-$1.2 billion and dispositions of $1.6-$2 billion, keeping capital recycling a central earnings and NAV driver.

Camden has a healthy balance sheet with ample liquidity, positioning it well to capitalize on long-term growth opportunities. Liquidity increased to about $881.9 million as of March 31, 2026, consisting of cash and availability under the unsecured credit facility and commercial paper program. Credit metrics remain supported by interest expense coverage of 6.0X in first-quarter 2026 and an unencumbered real estate assets-to-unsecured debt ratio of 3.2, which helps fund development and acquisition activity without forcing near-term equity issuance.

Risks Likely to Affect CPT’s Positive TrendAn elevated supply of apartment units in some markets and portfolio concentration in certain regions raise concerns for Camden. High interest expenses add to the company’s woes.

Stocks to ConsiderSome better-ranked stocks from the residential REIT sector are Centerspace (CSR - Free Report) and Invitation Home (INVH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for CSR’s 2026 FFO per share is pegged at $4.85, moving marginally northward over the past month.

The consensus estimate for INVH’s full-year FFO per share is pinned at $1.95, being revised upward by a cent over the past month.

Note: Anything related to earnings presented in this write-up represents funds from operations (FFO), a widely used metric to gauge the performance of REITs.

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

The proposed transactions may contain terms that could limit superior competing offers.

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options.

Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options.

Allbirds, Inc.'s (NASDAQ: BIRD)'s sale of its intellectual property and certain other assets to American Exchange Group for $39 million. If you are an Allbirds shareholder, click here to learn more about your legal rights and options.

On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
One World Trade Center
85th Floor
New York, NY 10007
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.

Centessa insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

Also from this source

Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares are surging today, last seen 44.4% higher to trade at $39.90 on news that Eli Lilly (LLY) will acquire the company for $6.3 billion. The move is part of the former's plans to diversify its metabolic portfolio with sleep disorder treatments.

Analysts chimed in on the update, with Needham and B. Riley downgrading CNTA to "hold" and "neutral," respectively, from "buy." Piper Sandler cut its rating to "neutral" from "overweight." Analysts were bullish coming into today, with 16 of the 17 in coverage sporting "buy" or better ratings.

Options traders are targeting CNTA, too, with 3,467 calls and 2,687 puts traded so far -- 11 times the volume typically seen at this point. Most active is the April 30 call, followed by the December 22.50 puts.

CNTA is headed for its best day on record and earlier scored an all-time high of $40.26. The shares are staging a bounce off the rising 40-day moving average, and now sport a more than 203% nine-month lead.

Shares of Centessa Pharmaceuticals (CNTA 0.14%) surged on Tuesday after the drugmaker struck a deal to be acquired by Eli Lilly (LLY 0.51%) for as much as $7.8 billion.

Image source: Getty Images.

An enticing offer for Centessa's investors Under the terms of the deal, Lilly would purchase Centessa for $38 per share in cash. That's a premium of nearly 38% to the healthcare stock's closing price on Monday.

Centessa's shareholders would also receive a non-transferrable contingent value right, which could be valued at up to $9 per share if the pharmaceutical company's investigational drugs achieve certain regulatory milestones.

The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval.

Today's Change

(

-0.14

%) $

-0.06

Current Price

$

39.70

Advancing neuroscience Centessa is developing a novel class of drugs, known as orexin receptor 2 (OX2R) agonists, to treat daytime sleepiness and other neurological conditions. Its most promising experimental drug, cleminorexton, showed best-in-class potential in Phase 2 clinical studies for severe sleep disorders, including narcolepsy and idiopathic hypersomnia.

"Orexin receptor biology represents one of the most compelling mechanistic opportunities in neuroscience as a direct intervention on the master switch of the sleep-wake cycle," Lilly executive Carole Ho said. "Centessa has assembled a portfolio with the breadth and depth to improve wakefulness across a broad array of indications."

Blockbuster potential Lilly is wisely using the windfall from its highly successful GLP-1 drugs Mounjaro and Zepbound to diversify its development pipeline. Centessa's experimental therapies could become top sellers in a potential $20 billion market for treatments for severe sleep conditions, according to investment bank Oppenheimer.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Centessa Pharmaceuticals Plc. The Motley Fool has a disclosure policy.

© mezzotint / Shutterstock.com

Pre-Market Stock Futures: Futures are trading higher after an explosive rally on Tuesday, sparked by the President’s comments that he wants to end the war soon. While this is hardly the final straw for the war, it appears that President Trump, who is finally getting some support from NATO members and Persian Gulf allies in the fight against Iran and its paid proxies, may be making some progress. Add in the fact that Iran’s infrastructure and weaponry have been devastated, and many of the military and Revolutionary Guard leaders have been killed. Toss in the massive short interest, and it all adds up to Tuesday’s huge rally, with the Nasdaq as the big winner, closing up a stunning 3.83% at 21,590, and the small-cap Russell 2000 not far behind, finishing the session at 2,496, up 3.41%. The S&P 500 closed Tuesday at 6,528, up 2.91%, and the Dow Jones Industrial finished the clean sweep of winners, closing at 46,341, up 2.49%.

Treasury Bonds: Yields were lower across the curve, except at the very short T-bills and the long end, as buyers returned, as they did on Monday. Some of the same reasons we have cited recently for bond prices rising (and yields falling) were again driven by safe-haven demand amid intensified Middle East conflict. Investors shifted from fears of inflation to concerns about slower global growth, prompting a “bull steepening” of the yield curve and a rebound after a month of heavy selling.

Oil and Gas: Prices were mixed across the energy complex, which experienced severe intraday volatility, initially dropping on reports of a potential de-escalation in Iran but remaining supported by lingering anxieties over supply disruptions, particularly after a tanker was hit near Dubai. Toss in futures contract expirations, and the stage was set for a crazy end to the quarter. Brent Crude closed up 4.94% at $118.30, while West Texas Intermediate closed down at $101.50, down 1.33%. Natural Gas finished the day at $2.84, dowm 0.10%. 

Gold: The precious metals joined in on the rally as gold, which has traded in a tight range for the better part of the first quarter, had an impressive day, closing trading up a whopping 3.49% at $4,667, while Silver really had some momentum buying and was last seen on Tuesday at $75, up a strong 7.18%. Wall Street analysts attributed the big moves higher to the recent decline to market overreaction, as investors moved to buy the dip. This rebound suggests a resilient bullish sentiment, even as the market grapples with rising oil prices, inflationary pressure, and weakening consumer confidence.

Crypto: The cryptocurrency market endured a turbulent session marked by sharp price swings but demonstrated solid resilience, holding firm at key support levels amid heightened geopolitical tensions. Developments heavily influenced risk sentiment across the broader crypto space, as traders responded swiftly to shifting headlines. Bitcoin led the volatility, surging to an intraday high of $68,300 in early trading after reports emerged of potential peace negotiations between Iran and Israel briefly lifted market optimism. However, the rally proved short-lived, with the crypto giant retracing to a consolidation range of $67,000–$67,800 as uncertainty resurfaced and profit-taking set in. The speed of the reversal underscored how sensitive the market remains to geopolitical developments, with algorithmic trading and leveraged positions amplifying the intraday swings. At 8 AM EDT, Bitcoin was trading at $68,680 while Ethereum was quoted at $2,135. 

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock. 

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Wednesday, April 1, 2026.  

Upgrades: Formula One Group (NASDAQ: FWONK | FWONK Price Prediction) was raised to Buy from Neutral at Bank of America, which has a $105 price target for the shares. Rivian Automotive Inc. (NASDAQ: RIVN) was upgraded to Neutral from Underperform at DA Davidson, with a $14 target price. United Health Group Inc. (NYSE: UNH) was upgraded to Outperform from Market Perform at Raymond James, which posted a $330 target price objective. Walt Disney Company (NYSE: DIS) was raised to Outperform from Market Perform at Raymond James, which has a $115 target for the entertainment giant. Wells Fargo & Company (NYSE: WFC) was upgraded to Buy from Hold at HSBC, with a $94 target price. Downgrades:
Apellis Pharmaceutical Inc. (NASDAQ: APLS) was downgraded to Hold from Buy at Stifel with a $41 target price as Biogen is acquiring the company. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Market Perform from Outperform at Leerink, with a $40 target, as Eli Lilly is acquiring the company. First Citizens Bancshares Inc. (NASDAQ: FCNCA) was cut to Neutral from Overweight at JPMorgan, which dropped the target price for the shares to $2,200 from $2,450. Nike Inc. (NYSE: NKE) was downgraded to Neutral from Overweight at JPMorgan, which slashed the target price for the sports apparel and shoe giant to $52 from $86. PPG Industries Inc. (NYSE: PPG) was downgraded to Neutral from Buy at Citigroup, which trimmed the target price for the stock to $113 from $132. Initiations: Boeing Company (NYSE: BA) was initiated with an Overweight rating at Wells Fargo, which has a $250 target price for the aerospace giant.
Datadog Inc. (NASDAQ: DDOG) was started with a Buy rating at Benchmark, with a $150 target price. Northrop Grumman Corp. (NYSE: NOC) was started with an Overweight rating at Wells Fargo, with an $800 target price objective. Rocket Lab Corp. (NASDAQ: RKLB) was initiated with an Equal Weight rating at Wells Fargo, with a $60 target price. ServiceNow Inc. (NYSE: NOW) was initiated with a Buy rating at Benchmark with a $125 target price.

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Centessa Pharmaceuticals plc (NASDAQ: CNTA) related to its sale to Eli Lilly and Company. Under the terms of the proposed transaction, Centessa shareholders are expected to receive $38.00 per share in cash and one non-transferable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/centessa-pharmaceuticals-plc/. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Centessa (NASDAQ: CNTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Lilly.

Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Centessa stockholders will receive $38.00 per share in cash plus contingent value rights worth up to $9.00 per share. The contingent value rights entitle holders to receive up to three milestone payments: $2.00 upon U.S. FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030. All approvals must occur within five years of transaction closing.

Centessa insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Centessa by imposing a significant penalty if Centessa accepts a competing bid. We are investigating the conduct of the Centessa board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

© Chaay_Tee / iStock via Getty Images

Pre-Market Stock Futures: Futures are trading lower this morning after negotiations with Iran failed over the weekend, and President Trump indicated the U.S. will block the Strait of Hormuz. This comes as we get set to start the first-quarter earnings season this week, as the major money-center banks and brokerage firms begin to report results today and tomorrow. The stock market ended last week higher, but it was a grind, with big swings throughout. When trading ended Friday, the market posted its best week since November. All the major indices finished Friday lower, except the Nasdaq, which closed at 22,902, up 0.35%. The Dow Jones Industrials were the loss leader on Friday, closing down 0.56% to finish at 47,916,  while the Russell 2000 was last seen at 2,630, down 0.22%. The venerable S&P 500 almost broke even by the close, finishing Friday’s session down just 0.11% at 6,816.

Treasury Bonds: After a solid week for the Treasury market, sellers returned on Friday as yields rose across the entire curve, driven by persistent worries about inflation and perceived growing geopolitical instability in the Middle East, with oil-driven inflation fears continuing to pressure the market.  Markets are adjusting to a more hawkish Federal Reserve, as traders price in higher interest rates that lower the value of existing bonds. Plus, there is a major issue for the bond market, given the mounting inflation in recent reports, that there could be no interest rate cuts in 2026. The 30-year-long bond closed Friday at 4.91%, while the benchmark 10-year note closed at 4.32%. 

Oil and Gas: After a wild week across the energy complex, oil finished in positive territory for consumers, as both major benchmarks finished lower on the day, trading below the pivotal and psychological $100 level. Brent Crude closed Friday at $94.29, down 1.60%, while West Texas Intermediate finished the week at $96.57, down 1.33%. Natural gas also finished the day and the week lower, closing at $2.65, down 0.82%.

Gold: The precious metals complex, like all the other major sectors, finished a volatile week on a quieter note on Friday. Gold closed the session at $4,747, down 0.38%, while Silver closed modestly higher at $75.76, up 0.55%. 

Crypto: Crypto markets traded in a “risk-off” mode on Friday, with Bitcoin holding above $72,000 as investors braced for inflation data that came in higher than expected. The market saw a tentative recovery following a broader corrective phase, with Ethereum holding just above key support levels while trading above the 50-day exponential moving average. The Cryptocurrency arena remains fragile and cautious as market participants analyze March’s hot Consumer Price Index (CPI) data, which indicated mounting inflationary pressure. At 7 AM EDT, Bitcoin was trading at $70,825, while Ethereum was quoted at $2, 184. 

24/7 Wall St. reviews dozens of analyst research reports daily to identify new investment ideas for both investors and traders. Some of these daily analyst calls cover stocks to buy. Other calls cover stocks to sell or avoid. Remember that no single analyst call should ever be used as a basis to buy or sell a stock.

Here are some of the top Wall Street analyst upgrades, downgrades, and initiations seen on Monday, April 13, 2026.  

Upgrades: Bilibili Inc. (NASDAQ: BILI) | BILI Price Prediction was upgraded to Overweight from Equal Weight at Morgan Stanley, which raised the target price to $31 from $25. Constellation Brands Inc. (NYSE: STZ) was upgraded to Buy from Hold at TD Cowen, which raised the price target for the stock to $190 from $142. CoreWeave (NASDAQ: CRWV) was upgraded by Macquerie to Outperform from Neutral, which raised the target price for the stock to $125 from $90. Starbucks Corp. (NASDAQ: SBUX) was raised to Hold from Underperform at Jefferies, which boosted the target price for the ubiquitous coffee retailer to $92 from $86. T-Mobile US Inc. (NASDAQ: TMUS) was upgraded to Overweight from Sector Weight at KeyBanc, with a $260 target price objective. Downgrades: Best Buy Inc. (NYSE: BBY) was double downgraded to Sell from Buy at Goldman Sachs, which lowered the price target for the retailer to $59 from $76. Centessa Pharmaceuticals Inc. (NASDAQ: CNTA) was downgraded to Hold from Buy at Truist with a $38 target price. This is the amount Eli Lilly is paying to purchase the company. Hewlett Packard Enterprise Co. (NYSE: HPE) was downgraded to Outperform from Strong Buy at Raymond James, which trimmed the target price for the legacy tech giant to $29 from $30. Nebius Group NV (NASDAQ: NBIS) was downgraded to Hold from Buy at Freedom Capital, which raised the target price for the stock to $154 from $108. Nike Inc. (NYSE: NKE) was downgraded to Hold from Buy at HSBC, which slashed the target price for the sporting apparel and shoe giant to to $48 from $90. Initiations: Adobe Inc. (NASDAQ: ADBE) was initiated with a Neutral rating at BTIG, with no price target posted. 
Credo Technology Group Holding Ltd. (NASDAQ: CRDO) was initiated with a Buy rating at Jefferies, which has set a $175 target price for the company. Johnson Controls Inc. (NYSE: JCI) was initiated with an In Line rating at Evercore ISI, with a $155 target price. Rollins Inc. (NYSE: ROL) was started with a Hold rating at Loop Capital, which has set a $56 target price for the shares. Tempus AI Inc. (NASDAQ: TEM) was started with an Underperform rating at Jefferies, with a $35 price target.

-

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Centessa Pharmaceuticals plc (NasdaqGS: CNTA) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Centessa will receive $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

More News From Kahn Swick & Foti, LLC

Back to Newsroom

Proven Chief Medical Officer at several publicly listed and clinical-stage oncology companies with successful track record developing multiple modalities including radiotherapies from preclinical through global approvals across hematologic malignancies and solid tumors Played a leading role in clinical development and worldwide approvals of Erbitux® at Merck KGaA leading to its blockbuster status Led clinical development as CMO of NBE Therapeutics which was acquired by Boehringer Ingelheim for $1.4 billion, and most recently CMO of radiotherapy company Full-Life Technologies Timely key hire with Dr. Heeger's operational rigor and clinical expertise expected to elevate development of Actimab-A, ATNM-400, and Iomab-ACT as Actinium advances toward key data readouts and expanded clinical trials in 2H:2026 , /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced the appointment of Steffen Heeger, MD, MSc, as Chief Medical Officer. Dr. Heeger brings a rare combination of radiotherapy expertise, global oncology drug development leadership, and public-company experience.  Over his career, he has translated multiple programs from IND submission through global clinical approval in the US, EU, and Japan including the blockbuster Erbitux® and led as CMO an oncology company acquired for $1.4 billion.  Most recently Dr. Heeger served as CMO of a clinical-stage radiotherapy company where he advanced into global development, a PSMA program directly relevant to Actinium's ATNM-400 asset. His appointment comes at a pivotal moment as Actinium prepares to advance Actimab-A, ATNM-400, and Iomab-ACT toward key data readouts and expanded clinical trials in the second half of 2026.

"Steffen's background is uniquely suited to unlock the value in Actinium's pipeline" said Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals. "He has successfully taken multiple targeted oncology and radiotherapy programs from the lab into patients, including anti-PSMA programs directly relevant to our ATNM-400 asset, and has deep experience navigating global regulatory pathways with the FDA and international agencies. Steffen brings precisely the combination of deep radiotherapy expertise, global oncology clinical development leadership, regulatory experience, and executional intensity that we need as we advance and expand our pipeline of targeted radiotherapies."

"Importantly, Steffen's experience spans both hematologic malignancies and solid tumors, aligning exceptionally well with our strategic focus of building Actinium into a leading targeted radiotherapy company." Mr. Seth added. "His direct experience with alpha-emitting radiotherapies, translational medicine, and global clinical execution will be highly valuable as we progress our clinical programs and pursue new opportunities to unlock the full potential of our platform. Few clinical leaders know radiotherapy development as deeply as Steffen does, and fewer still pair that with the public-company experience and translational oncology track record he brings. We are thrilled to welcome him to Actinium."

Prior to Actinium, Dr. Heeger served as Chief Medical Officer of Full-Life Technologies, where he led global development, regulatory affairs, clinical operations, translational research, CMC, quality assurance, and program management for the company's radiotherapy pipeline. There he led the translation of three targeted radioconjugate compounds — including an anti-PSMA program in metastatic castration-resistant prostate cancer — from preclinical to clinical stage within two years, securing IND clearance and fast track designation. Prior to Full-Life, he was CMO of Pega-One, a clinical-stage oncology company that became part of Centessa Pharmaceuticals (Nasdaq: CNTA) ahead of its $380 million initial public offering. Earlier, he served as CMO of NBE-Therapeutics, where he led the IND submission and initial clinical trial of NBE-002, a first-in-class immune-stimulatory antibody-drug conjugate targeting ROR1 in triple-negative breast cancer, non-small cell lung cancer, and sarcoma. NBE-Therapeutics was subsequently acquired by Boehringer Ingelheim for $1.4 billion. Before NBE, Dr. Heeger was CMO of Selvita S.A. (WSE: SLV), where he advanced the company's lead anti-cancer compound through IND and into its first clinical trial.

Earlier in his career, Dr. Heeger served as Vice President, Head of Clinical Development at MorphoSys AG, where he led the clinical strategy and execution of the company's lead hematology and oncology programs, including monoclonal antibody therapeutics targeting CD19, CD38, and PSMA. He began his pharmaceutical career at Merck KGaA, where over nearly a decade, he led global clinical development and life cycle management for Erbitux® (cetuximab) across colorectal, head and neck, gastric, and lung cancers in major markets including the US, Europe, Japan, and China enabling its blockbuster status.

"Actinium is developing what I believe is one of the most compelling radiotherapy pipelines today." said Dr. Heeger. "Their biology-driven R&D has yielded several highly differentiated, even unique, assets that  offer real opportunity to bring transformative therapies to patients with limited options. Their assets have nothing comparable being developed and each has blockbuster potential; ATNM-400 with its novel target and compelling data across the largest solid tumor indications, Actimab-A's promise to resensitize immune checkpoint inhibitors in solid tumors and backbone potential in hematological malignancies, as well as their cell and gene therapy conditioning agent Iomab-ACT.  These are exactly the kinds of assets I have spent my career developing. I am honored to join Actinium at this pivotal stage and look forward to working closely with Sandesh and our team to unlock the value in our clinical programs."

Dr. Heeger holds an MD and a Master of Healthcare Management (MSc) from the University of Heidelberg, Germany, a world-leading institution for research in nuclear medicine and targeted radionuclide therapies. He trained as a clinical oncologist at the University Hospital Heidelberg, Department of Haematology and Oncology, and at the German Cancer Research Center. He has authored and co-authored more than 20 peer-reviewed publications across oncology and radiopharmaceutical research. Notably, Dr. Heeger's scientific roots include early work in alpha-radiotherapy, including published research involving alpha-radioimmunotherapy using antibody conjugates in hematologic malignancies which bring him to a full cycle at Actinium.

About Actinium Pharmaceuticals, Inc.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.

Forward-Looking Statements

This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements, including statements as related to regaining compliance with the rules of the NYSE American and submission of a compliance plan, are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

Investors:
[email protected]

SOURCE Actinium Pharmaceuticals, Inc.

31 March 2026 – Alstom, a global leader in smart and sustainable mobility, is pleased to announce that it has signed a new systems contract in the AMECA region, as part of a consortium, with a total project value of USD 2.75 billion. Alstom’s share represents approximately 30% of the total contract value, corresponding to approximately EUR 700 million.

This order has been recorded in Alstom’s Q4 2025/2026 fiscal year.

Alstom™ is a protected trademark of the Alstom Group. 

 About Alstom  Alstom commits to contribute to a low carbon future by developing and promoting innovative and sustainable transportation solutions that people enjoy riding. From high-speed trains, metros, monorails, trams, to turnkey systems, services, infrastructure, signalling and digital mobility, Alstom offers its diverse customers the broadest portfolio in the industry. With its presence in 63 countries and a talent base of over 86,000 people from 184 nationalities, the company focuses its design, innovation, and project management skills to where mobility solutions are needed most. Listed in France, Alstom generated sales of €18.5 billion for the fiscal year ending on 31 March 2025.
For more information, please visit www.alstom.com.   ContactsPress
Coralie COLLET - Tel.: +33 (0) 7 63 63 09 62 
[email protected] BEKHTI –Tel.: +971 56 995 45 76

[email protected] Relations
Cyril GUERIN - Tel.: +33 (0)6 07 89 36 16
[email protected]

 Guillaume GAUVILLE - Tel: +44 (0)7 588 022 744
[email protected]

 Jalal DAHMANE - Tel: +33 (0)6 98 19 96 62
[email protected]

  20260331_Note for investors_AMECA_ENG

08 April 2026 – Alstom, a global leader in smart and sustainable mobility, is pleased to announce that it has received a Signalling contract in the Europe region for approximately €295 million.

This order was booked in Alstom’s Q4 2025/2026 fiscal year.

Alstom™ is a protected trademark of the Alstom Group. 

 About Alstom  Alstom is the pure rail leader, committed to making rail the backbone of sustainable transportation. We design and deliver a
complete range of future-ready solutions – from high-speed and regional trains to metros, monorails, trams, turnkey systems,
end-to-end services, infrastructure, signalling and digital rail solutions. With 86,000 people in 63 countries, Alstom brings
together global expertise and multi-local presence to make every journey smarter, cleaner and more enjoyable. Together with
our partners and customers, we realise the power of rail. Listed in France, Alstom generated revenues of €18.5 billion for the
fiscal year ending 31 March 2025.
For more information, please visit www.alstom.com.   ContactsPress
Coralie COLLET - Tel.: +33 (0) 7 63 63 09 62 
[email protected] Relations
Cyril GUERIN - Tel.: +33 (0)6 07 89 36 16
[email protected]

 Guillaume GAUVILLE - Tel: +44 (0)7 588 022 744
[email protected]

 Jalal DAHMANE - Tel: +33 (0)6 98 19 96 62
[email protected]

  20260408_Note for investors_ENG

Alstom SA (ALSMY) Q4 2026 Earnings Call Transcript

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Alstom S.A. (OTC: ALSMY; AOMFF). The investigation focuses on Alstom’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Alstom securities?
If you purchased Alstom securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.

There is no cost or obligation to you.

Background of the investigation
On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026. Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%.

The Company further stated that “some large rolling-stock projects have progressed more slowly than anticipated,” weighing on near-term margins and cash. In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and stated that its prior medium-term ambition of adjusted EBIT margin of 8–10% would no longer be met by the end of its next fiscal year.

Following this disclosure, the price of Alstom’s stock declined sharply, damaging investors.

In light of this disclosure, Johnson Fistel is investigating whether Alstom complied with the federal securities laws. If you suffered losses from your investment in Alstom stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected]

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026.  Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%.  The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash.  In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year. 

Following these disclosures, Alstom's stock price fell sharply, damaging investors.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026.  Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%.  The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash.  In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year. 

Following these disclosures, Alstom's stock price fell sharply, damaging investors.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

13 May 2026 - Alstom, global leader in smart and sustainable mobility, reports financial results for the fiscal year FY 2025/26. Martin Sion, Chief Executive Officer of Alstom, said:

, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alstom S.A. ("Alstom" or the "Company") (OTCMKTS: ALSMY; AOMFF).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Alstom and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On April 16, 2026, Alstom S.A. announced preliminary unaudited results for the fiscal year ended March 31, 2026.  Among other things, the Company disclosed that it manufactured 4,284 cars during the fiscal year and that adjusted EBIT margin stood at around 6%.  The Company further disclosed that "some large rolling-stock projects have progressed more slowly than anticipated," weighing on near-term margins and cash.  In addition, Alstom disclosed free cash flow of approximately €330 million, withdrew its three-year cumulative €1.5 billion free cash flow guidance, and said that its prior medium-term ambition of adjusted EBIT margin of 8-10% would no longer be met by the end of its next fiscal year. 

Following these disclosures, Alstom's stock price fell sharply, damaging investors.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes. 

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP